Description

Indication: Lymphomas, b-cell (expressing cd20)
 
AME-133v is hypothesized to result in an anti-CD20 therapy with greater potency and efficacy in all patients, but particularly in genetically defined subpopulations that respond poorly to rituximab (Rituxan)  because they express a low affinity version of the Fc receptor on their immune effector cells. A monoclonal antibody that has increased binding for this receptor should be more effective in stimulating effector cell killing and thus improve response to the antibody. This study is designed to provide evidence of the safety and a preliminary understanding of the efficacy of AME 133v

Compared to existing CD20 antibodies GA101 represents a novel, third generation antibody with significantly enhanced efficacy in a variety of in vitro and in vivo preclinical models. GA101 constitutes the first type II CD20 antibody successfully engineered for increased ADCC. Based on these data, GA101 is a promising therapeutic antibody candidate for the treatment of B-cell malignancies.  
ASH 2007

Indication: lymphoma, not yet specified

Immunomedics Patents Internalizing Anti-CD74 Antibodies  Reuters 

 
Indication: Lymphomas 

CAT-8015 is an optimized version of  CAT-3888 with increased affinity for CD22. CD22 is a cell surface receptor expressed in a wide variety of B-cell malignancies. The anti-CD22 immunotoxin CAT-8015 comprises a dsFv that targets the CD22 receptor, fused with a specifically engineered toxin molecule that minimizes non-targeted toxicity, resulting in a highly specific, highly potent therapeutic molecule. The molecule acts by releasing the toxin intracellularly, after the whole immunotoxin has been internalised via the CD22 receptor.
" 

Indication: Lymphomas, b-cell 

Scant background information so far; one trial

Intravenous Bispecific Antibody (4G7XH22) 

 
Indication: Lymphomas expressing cd20
 
"radioimmunotherapy (RAIT) using epratuzumab to deliver toxic radiation directly to lymphoma cells in small fractions." Source

APPROVED for relapsed indolent lymphoma. See Bexxar

Indication: Lymphomas, b-cell (expressing cd20) 
 
(iodine I 131 tositumomab)

Indication: MDS
 
"The therapy involves infusing donor T lymphocytes engineered with a gene encoding an inactive apoptosis protein."

In immunology, APO866 exerts inhibitory effect on T-cells offering the potential as a treatment for autoimmune diseases " - Source

 ... AT-101 induces apoptosis in primary leukemia cells from patients with CLL. This effect is concentration dependent (IC50= 2μM) and it is independent of the expression of prognostic factors such as ZAP-70 or IgVH gene mutational status in the leukemia cells.

- AT-101 seems to have stronger pan-specific binding affinity for Bcl-2 family proteins than racemic gossypol, in particular to Mcl-1 and Bcl-XL. "

Background article PDF

 - Source | See also CLLtopics overview

 - Source  

The inhibition of the antiapoptotic Bcl-2 proteins is an attractive strategy for either restoring normal apoptotic process in cancer cells or making these cells more susceptible to conventional chemotherapy. - Source

 
Indication: Lymphoma, follicular
 
"CpG oligodeoxynucleotides (CpG-ODNs) affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing antibody-dependent cell-mediated cytotoxicity (ADCC)" Source

Indication: Lymphoma, cutaneous b- or t-cell
 
TG1042 is a third-generation, nonreplicating human adenovirus vector containing a human IFN-gamma cDNA insert." Source
Data: http://www.biovalley.com/images_messages/image2/749.pdf 

CPG-7909 (PF-3512676, ProMune^®): toll-like receptor-9 agonist in cancer therapy  expertopin.com 

Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleotides (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy.

Indication: Lymphomas
 
Novel anti-sense "The inactivation of MYC may be a specific and effective treatment for these tumors. To address for this possibility, I have developed a novel mouse model system to conditionally regulate MYC expression in mouse lymphocytes. Previously, I have used this model system to demonstrate that the inactivation of MYC can be sufficient to cause the sustained regression of cancers." Source

Indication: Lymphomas
 
NBAY 43-9006 is a "targeted drug" specifically engineered to inhibit something called the RAF kinase within the cancer cells. RAF in turn is part of the RAS oncogene pathway. RAS is a gene which drives cell division and is overexpressed in many cancers, including RCC. Source

Indication: Lymphoma, t-cell cutaneous
 
(Forodesine) PNP-inhibitor. May stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.

ASH: Forodesine HCl active single oral agent for advanced refractory CTCL abstracts2view.com

"temsirolimus (CCI-779), an inhibitor of mTOR kinase used as single agent achieved an overall response rate of 38% in relapsed MCL patients. Source 

Single-agent CCI-779 has substantial anti-tumor activity in relapsed MCL. This study demonstrates that agents, which selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit. The high response rate warrants further studies of this agent in MCL, but the high incidence of hematologic toxicity suggests that a lower dose should be explored. CCI-779 at 25mg is currently being evaluated in MCL through an NCCTG trial Abstract #129 appears in Blood, Volume 104, issue 11, November 16, 2004 " 

CS-1008 (humanized anti-DR5 antibody)